Fractyl Health to present new data on Rejuva Smart GLP-1 program

Fractyl Health (GUTS) will present new data from its preclinical Rejuva Smart GLP-1 pancreatic gene therapy program in a poster titled “Feasibility and Safety of Novel Endoscopic Ultrasound-Guided Delivery of Human GLP-1 Pancreatic Gene Therapy in Pigs” at the 22nd World Congress Insulin Resistance, Diabetes & Cardiovascular Disease, WCIRDC. At Day 34 post-procedure pancreatic biopsies showed that active GLP-1 protein expression capacity within pancreatic islets was greatly enhanced. RJVA-001 achieved therapeutically relevant GLP-1 expression levels based on observations in disease models and were five times higher in treated than untreated animals. These results demonstrate the potential of RJVA-001 to dramatically enhance GLP-1 production capacity to therapeutically relevant levels without any observed adverse safety signals.